Tirzepatide vs Orforglipron: How the Weekly Injection and the Daily GLP-1 Pill Compare

Tirzepatide vs orforglipron is a question many people weighing weight management medication now ask, because the two options work in very different ways. Tirzepatide (Zepbound) is a peptide injected once a week that activates two hormone receptors, GIP and GLP-1, while orforglipron (Foundayo) is a small molecule tablet taken once a day that activates the GLP-1 receptor alone. Both are made by Eli Lilly, and orforglipron received its first FDA approval for long term weight management in April 2026 (Shirley, Drugs, 2026).

The two medicines have not been tested against each other in a single trial. Their pivotal obesity trials were, however, built in a similar way, which makes a careful side by side reading possible.

What is the difference between tirzepatide and orforglipron?

Tirzepatide and orforglipron differ in molecule type, receptor targets and dosing schedule. Tirzepatide is a peptide that the Zepbound prescribing information describes as a glucose dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, so it acts on two incretin pathways at once. Tirzepatide is given as an injection under the skin, as our guide to how tirzepatide works explains.

Orforglipron is described in its phase 3 trial report as a small molecule, nonpeptide oral GLP-1 receptor agonist, and that nonpeptide structure is what allows it to be absorbed from a tablet. It acts on the GLP-1 receptor only and has no GIP activity. Both medicines are indicated, with diet and physical activity, for long term weight management in adults with obesity, or with overweight and at least one weight related condition. The Zepbound label also covers moderate to severe obstructive sleep apnea in adults with obesity, an indication the Foundayo label does not carry.

How much weight did people lose on tirzepatide compared with orforglipron?

In their 72 week placebo controlled trials, average weight loss was larger with tirzepatide than with orforglipron. The SURMOUNT-1 trial (Jastreboff and colleagues, New England Journal of Medicine, 2022) enrolled 2,539 adults without diabetes and assigned them to tirzepatide 5 mg, 10 mg or 15 mg weekly, or placebo. Mean weight change at week 72 was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, compared with -3.1% on placebo.

The ATTAIN-1 trial (Wharton and colleagues, New England Journal of Medicine, 2025) enrolled 3,127 adults with obesity without diabetes and assigned them to orforglipron 6 mg, 12 mg or 36 mg daily, or placebo. Mean weight change at week 72 was -7.5% on 6 mg, -8.4% on 12 mg and -11.2% on 36 mg, compared with -2.1% on placebo. The Foundayo label presents these trial doses as equivalent marketed doses of 5.5 mg, 9 mg and 17.2 mg.

The difference is also visible at the high end of the response range. In SURMOUNT-1, 50% of people on tirzepatide 10 mg and 57% on 15 mg lost 20% or more of their body weight, compared with 3% on placebo. In ATTAIN-1, 18.4% of people on orforglipron 36 mg reached that threshold, compared with 2.8% on placebo, while 54.6% on the same dose lost 10% or more and 36.0% lost 15% or more.

Why is the tirzepatide and orforglipron comparison indirect?

The comparison is indirect because no randomized trial has placed tirzepatide and orforglipron in the same study, and comparisons across trials can be distorted by differences in who enrolled and how missing data were handled. SURMOUNT-1 and ATTAIN-1 are closer than most pairs, since both lasted 72 weeks and both excluded people with diabetes, but individual results vary widely in both programs. A genuine head to head design is described in our review of the tirzepatide vs semaglutide evidence.

How are tirzepatide and orforglipron taken?

Tirzepatide is injected once a week, and orforglipron is swallowed once a day. According to the Zepbound label, tirzepatide starts at 2.5 mg weekly for 4 weeks, then rises to 5 mg, and can increase in 2.5 mg steps after at least 4 weeks on each dose. The maintenance dose is 5 mg, 10 mg or 15 mg weekly, injected at any time of day with or without meals, and the full schedule is set out in our guide to the tirzepatide dose escalation ladder.

According to the Foundayo prescribing information, orforglipron is taken orally once daily with or without food, and the tablet must be swallowed whole. The starting dose is 0.8 mg, which increases to 2.5 mg after at least 30 days and then to 5.5 mg after at least another 30 days. Depending on response and tolerability, the dose can then rise to 9 mg, 14.5 mg or the maximum of 17.2 mg, with at least 30 days at each step.

The practical trade off is frequency against format: a weekly injection means 52 doses a year, while a daily tablet avoids needles but depends on remembering a dose every day.

What side effects do tirzepatide and orforglipron cause?

Both medicines most often cause gastrointestinal side effects, and in both trial programs these were mostly mild to moderate. The SURMOUNT-1 report notes that gastrointestinal events occurred primarily during dose escalation, and the Foundayo label describes nausea, vomiting and diarrhea easing after the escalation period.

In the pooled Foundayo weight management trials, nausea was reported by 26%, 34% and 35% of people on 5.5 mg, 9 mg and 17.2 mg, compared with 10% on placebo. Vomiting was reported by 13%, 21% and 24% compared with 4%, constipation by 20%, 27% and 24% compared with 9%, and diarrhea by 21%, 23% and 25% compared with 11%.

In SURMOUNT-1, adverse events led to discontinuation in 4.3%, 7.1% and 6.2% of people on tirzepatide 5 mg, 10 mg and 15 mg, compared with 2.6% on placebo. In ATTAIN-1, adverse events led to discontinuation in 5.3 to 10.3% of people across the orforglipron groups, compared with 2.7% on placebo.

Both labels carry a boxed warning about the risk of thyroid C-cell tumors. The Foundayo label adds that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but that the human relevance of the rodent findings seen with other GLP-1 medicines has not been determined.

Under both labels, the medicine should not be used by people with a personal or family history of medullary thyroid carcinoma, by people with multiple endocrine neoplasia syndrome type 2 (MEN 2), or by people with a known serious allergy to the drug. Both labels also list the same serious warnings: acute pancreatitis, acute gallbladder disease, acute kidney injury from dehydration after vomiting or diarrhea, low blood sugar when combined with insulin or an insulin secretagogue such as a sulfonylurea, and a risk of inhaling stomach contents during general anesthesia or deep sedation. Persistent severe abdominal pain, sometimes spreading to the back, is a reason to stop the medicine and seek prompt medical care, and anyone planning surgery or a sedated procedure should tell the care team they take either drug.

Do tirzepatide and orforglipron affect birth control pills?

Both labels advise people using oral birth control to switch to a non oral method or add a barrier method after starting and after each dose increase, for 4 weeks under the Zepbound label and 30 days under the Foundayo label. Contraceptives not taken by mouth are not expected to be affected, as our article on tirzepatide and oral birth control explains.

Can someone switch from tirzepatide to orforglipron?

A dedicated trial has tested this. The ATTAIN-MAINTAIN trial (Aronne and colleagues, Nature Medicine, 2026) randomized people previously treated with tirzepatide (205 participants) or semaglutide (171 participants) to daily orforglipron or placebo. At week 52, people in the tirzepatide cohort who switched to orforglipron maintained an estimated 74.7% of their earlier weight reduction, compared with 49.2% for those switched to placebo. In the semaglutide cohort, the figures were 79.3% with orforglipron and 37.6% with placebo.

The trial had no arm that stayed on the injectable medicine and lasted 1 year. It shows orforglipron did better than stopping treatment, not whether switching matches continuing tirzepatide. What tends to happen after GLP-1 treatment stops is covered in our article on weight regain after stopping GLP-1 therapy.

Who might consider tirzepatide or orforglipron?

The choice between tirzepatide and orforglipron is an individual clinical decision that depends on goals, health history and preferences. On the trial evidence, tirzepatide produced larger average weight loss and is also labeled for obstructive sleep apnea in adults with obesity. Orforglipron offers a needle free daily tablet without food timing rules, and ATTAIN-MAINTAIN suggests it may help some people keep much of the weight lost on an injectable medicine. Both labels state that the medicine may cause fetal harm and should be stopped when pregnancy is recognized, and a licensed clinician can weigh these factors against a person's medical history before recommending either option.